ERA
Endometrial Receptivity Analysis

Evaluates the status of the woman’s endometrial receptivity to prevent implantation failure

Scroll Down
 

Overview

  • ERA is a diagnostic test patented by IGENOMIX in 2009 that helps to evaluate the woman’s endometrial receptivity.
  • ERA identifies a patient’s unique “window of implantation” (WOI) leading to a personalized embryo transfer (pET).
  • 3 in every 10 patients have a displaced WOI. In such cases, a second endometrial biopsy is needed to identify when the patient is receptive.

More info

Overview

An endometrium is receptive when it is ready for embryo implantation. This occurs around days 19-21 in each menstrual cycle of a fertile woman. This period of receptivity is what we call the window of implantation.

The lack of synchronisation between the embryo ready to be implanted and endometrial receptivity is one of the causes of recurring implantation failure. This is why it is imperative to assess the endometrium in order to determine the optimal day for embryo transfer.

The ERA test requires an endometrial biopsy that should be carried out on day LH+7 (natural cycle) or day P+5 (HRT cycle). This biopsy is quickly and easily taken by a gynaecologist in their consultation room and sent to Igenomix for testing
The ERA test analyses the expression levels of 248 genes linked to the status of endometrial receptivity, using RNA sequencing taken from the endometrial tissue.

Following the analysis, a specific computational predictor classifies the samples according to their expression profile as Receptive or Non-Receptive.

 

The Endometrial Receptivity Anaysis (ERA®) has been designed, developed and patented by IGENOMIX (PCT/ES2009/000386)..

Benefits

  • ERA identifies the window of implantation (WOI) and recommends the best time for embryo transfer thereby increasing the chances of a successful outcome.
  • The ERA test has proven highly sensitive and accurate in detecting gene expression profiles associated with endometrial receptivity.
  • The ERA test resulted in a 73% pregnancy rate in patients with implantation failure.

     

    Ruiz-Alonso et al, Fertil Steril. 2013
    Clemente-Ciscar et al, 2018, submitted

Indications

    • Women who have experienced implantation failures with morphologically good quality embryos.
    • Women with a morphologically normal uterus and normal endometrial thickness (≥ 6 mm), where the uterus and endometrium are unlikely to be the problem.


Indications
Technology

Technology

The ERA test is performed with Next Generation Sequencing (NGS) technology

  • NGS is a scalable technology allowing large numbers of samples to be analyzed simultaneously.
  • NGS flexibility and accuracy has enabled the development of a new, improved predictor tool and will allow us to further enhance the test's effectiveness and include additional diagnostic markers.

More Info

Methodology

Methodology

Results will be delivered in 15 working days after receiving the samples in our lab.

Downloads & publications

Scientific publications and documents.

ERA publications

ERA publications

Other scientific documents

Other scientific documents

Our results

Our experts are professional, reliable and approachable and are available to help guide both professionals and patients throughout the entire process. We are proud to deliver high quality results for every test, every day.

More than

32K

ERA tests performed

70

countries

More than

1,000

clinics

16

scientific publications

Do you want to start using our Genetic Services?

For further assistance please contact our customer support team by phone or e-mail

Contact us

Igenomix is in the media

Igenomix is not affiliated with any news outlet or publication identified above. News coverage does not constitute an endorsement of Igenomix or its products.

Newsletter subscription